Compare Amphastar Pharmaceuticals Inc (AMPH) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs MakeMyTrip Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.94 (market cap $868.62M), while MakeMyTrip Ltd trades at $60.09 (market cap $5.78B). The key difference: MakeMyTrip Ltd is far larger — about 6.7× Amphastar Pharmaceuticals Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | MMYT | |
|---|---|---|
Market Cap | $868.62M | $5.78B |
Sector | Health | Technology |
52-Week High | $30.81 | $103.21 |
52-Week Low | $16.87 | $36.30 |
Enterprise Value | $1.27B | $6.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.86, down 2.22% today, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.
Outlook is cautious due to recent earnings misses and regulatory scrutiny, including an FDA warning letter. Analyst consensus leans Hold (66.67%) with limited Buy support. Key risks include competitive pressures and potential tariff impacts on generic drugs. Cash flow trends improved in 2026 with net cash flow rising to $36 million.
MakeMyTrip (MMYT) trades at $60.30, down 1.0% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2027 earnings that beat expectations despite revenue headwinds, maintaining robust gross margins of 73.45%. Recent news highlights growth in hotels and packages segments offsetting air travel softness, with analyst consensus strongly bullish at 73% buy ratings.
The outlook remains positive with earnings momentum and diversified travel services driving growth, though elevated P/E ratio of 267 and geopolitical travel disruptions present risks. Institutional sentiment supports upside potential with 34% average price target, while balance sheet strength provides stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
